Alternatively, similar analyses in comparing these preclinical models could be applied to other drugs in ovarian cancer treatment, such as paclitaxel, poly (ADP-ribose) polymerase (PARP) inhibitors and other drugs currently in preclinical studies such as HIF, WEE1 and TGFß inhibitors. This evidence concerns the gene WEE1 and ovarian cancer.